Upper Tract Urothelial Carcinoma – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of upper tract urothelial carcinoma (UTUC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of UTUC for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.

Clarivate Epidemiology’s UTUC forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with UTUC per year?
• How will improvements in survival change the number of people living with a diagnosis of UTUC?
• How will a declining risk of recurrence change the number of first-line drug-treatment opportunities for UTUC?
• Of all people diagnosed with UTUC, how many in each how many in each country in the developed world are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of UTUC over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology provides at least 10 years of forecast data for the following UTUC patient populations:

• Diagnosed incident cases of UTUC.
• Diagnosed incident cases of UTUC by stage at diagnosis.
• Diagnosed incident cases of UTUC by muscle-invasiveness at diagnosis.
• Diagnosed locally recurrent incident cases of UTUC.
• Diagnosed bladder recurrent incident cases of UTUC.
• Diagnosed bladder recurrent incident cases of UTUC by muscle-invasiveness.
• Diagnosed incident cases of metastatic recurrent UTUC.
• Diagnosed prevalent cases of UTUC.
• Drug-treatable non-muscle-invasive UTUC.
• Drug-treatable localized and resectable locally advanced UTUC.
• Diagnosed unresectable locally advanced or metastatic UTUC 1^st line drug-treatable population.

… and more (details available on request).

Note: Coverage may vary by country.